EffRx Announces Changes in the Composition of the Board of Directors

Freienbach, June 14th, 2016 — EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for orphan and specialty indications, today announced the appointment of Dr. Jonas Ekblom as Chairman and Dr. Alcide Barberis as Member of the Board of Directors.

“I feel elated to join the Board of this exciting company and I look forward to working with the Management team and the Board of Directors as we progress EffRx into its next phase of consolidation, maturation and growth,” commented Dr. Jonas Ekblom, Chairman.

Dr. Ekblom and Dr. Barberis will be replacing Mr. Oscar Ahlgren, Mr. Carl-Gustaf Johansson and Mr. Thomas Mårtensson who have stepped down from their current role as Directors. During their tenure they have successfully managed the transition of EffRx to become an integrated pharmaceutical company with its flagship program, Binosto®, being now commercialized in 10 key countries across Europe, Asia and America. Mr. Anders Wiklund will continue to serve as a Board Director and with his accomplished industry experience will ensure a smooth transition within the Board.

Dr. Jonas Ekblom brings over 20 years of experience from the life science sector, with a focus in pharmacology and drug development. He has managed R&D programs in in several therapeutic areas. Dr. Ekblom has business experience from US, EU and Asia.

Dr. Alcide Barberis is a biotech entrepreneur and manager with over 20 years management experience in the biotechnology industry and scientific experience in the private and public research sectors.